Flindr Therapeutics

📍 Oss, Netherlands🗓 Founded 2000👥 16 employees💰 Last funded Apr 2024
Biotechnology Research🌐 flindrtx.com
Website LinkedIn
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology).
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
2000
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
2
Frequently asked questions
Who invested in Flindr Therapeutics?
Flindr Therapeutics has 2 investors on record on gritt.io.
When did Flindr Therapeutics last raise funding?
The most recent investment in Flindr Therapeutics recorded on gritt.io was in April 2024.
When was Flindr Therapeutics founded?
Flindr Therapeutics was founded in 2000.
What industry is Flindr Therapeutics in?
Flindr Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Flindr Therapeutics based?
Flindr Therapeutics is headquartered in Oss, Netherlands.